Gunnar Tepe1,2, Thomas Zeller3, Matej Moscovic4, Jean-Marc Corpataux5, Johnny Kent Christensen6, Koen Keirse7, Giovanni Nano8, Henrik Schroeder9, Christoph A Binkert10, Marianne Brodmann11. 1. Department of Radiology, Klinikum Rosenheim, Rosenheim, Germany. gunnar.tepe@ro-med.de. 2. Institut für Diagnostische Und Interventionelle Radiologie, RoMed Klinikum Rosenheim, Pettenkoferstr. 10, 83022, Rosenheim, Germany. gunnar.tepe@ro-med.de. 3. Clinic Cardiology and Angiology II, Universitäts-Herzzentrum Freiburg - Bad Krozingen, Bad Krozingen, Germany. 4. Angiology Clinic, Institute of Cardiovascular Diseases, Kosice, Slovakia. 5. Department of Vascular Surgery, Lausanne University Hospital, Lausanne, Switzerland. 6. Department of Radiology, Kolding Hospital, Kolding, Denmark. 7. Department of Vascular Surgery, Regional Hospital Heilig Hart, Tienen, Belgium. 8. 1st Vascular Surgery Department, IRCCS Policlinico San Donato, San Donato Milanese, Italy. 9. Center for Diagnostic Radiology and Minimally Invasive Therapy, Jewish Hospital, Berlin, Germany. 10. Radiology Institute, Kantonsspital Winterthur, Winterthur, Switzerland. 11. Division of Angiology, Department of Internal Medicine, Medical University Graz, Graz, Austria.
Abstract
PURPOSE: After promising small randomized trials, the aim of BIOLUX P-III was to further investigate the safety and performance of the Passeo-18 lx drug-coated balloon in infrainguinal arteries under real-world conditions. METHODS: BIOLUX P-III is a global prospective single-arm study with follow-up at 6, 12 and 24 months. The primary safety endpoint was freedom from major adverse events (MAE) within 6 months. The primary performance endpoint was freedom from clinically driven target lesion revascularization (TLR) within 12 months. RESULTS: 877 patients/1084 lesions were enrolled. Diabetes mellitus was present in 47.7%, and 42.1% had critical limb ischemia (CLI). The mean lesion length was 89.0 mm with 76.1% of calcified lesions, and 24.9% occluded. At 24 months, freedom from MAE was 83.1% in the full cohort; 84.9% in the femoropopliteal population (592 patients, 691 lesions); 77.7% for long lesions (187 subjects/192 lesions); and 72.5% in the in-stent restenosis (ISR) subgroup (103 subjects/116 lesions). Twenty-four-month freedom from clinically driven TLR was 88.1% in the full cohort; 88.9% in the femoropopliteal population; 80.3% for the long lesions; and 78.4% for ISR. Twenty-four-month all-cause mortality was 12.0% in the full cohort, 10.2% in the femoropopliteal population, 14.8% for the long lesions and 12.0% for ISR. There was no device- or procedure-related death up to 24-month follow-up. CONCLUSION: The BIOLUX P-III 24-month outcomes confirm the safety and performance of Passeo-18 lx in infrainguinal arteries in a large population treated under real-world conditions with low complication rates and good clinical outcomes (NCT02276313).
PURPOSE: After promising small randomized trials, the aim of BIOLUX P-III was to further investigate the safety and performance of the Passeo-18 lx drug-coated balloon in infrainguinal arteries under real-world conditions. METHODS: BIOLUX P-III is a global prospective single-arm study with follow-up at 6, 12 and 24 months. The primary safety endpoint was freedom from major adverse events (MAE) within 6 months. The primary performance endpoint was freedom from clinically driven target lesion revascularization (TLR) within 12 months. RESULTS: 877 patients/1084 lesions were enrolled. Diabetes mellitus was present in 47.7%, and 42.1% had critical limb ischemia (CLI). The mean lesion length was 89.0 mm with 76.1% of calcified lesions, and 24.9% occluded. At 24 months, freedom from MAE was 83.1% in the full cohort; 84.9% in the femoropopliteal population (592 patients, 691 lesions); 77.7% for long lesions (187 subjects/192 lesions); and 72.5% in the in-stent restenosis (ISR) subgroup (103 subjects/116 lesions). Twenty-four-month freedom from clinically driven TLR was 88.1% in the full cohort; 88.9% in the femoropopliteal population; 80.3% for the long lesions; and 78.4% for ISR. Twenty-four-month all-cause mortality was 12.0% in the full cohort, 10.2% in the femoropopliteal population, 14.8% for the long lesions and 12.0% for ISR. There was no device- or procedure-related death up to 24-month follow-up. CONCLUSION: The BIOLUX P-III 24-month outcomes confirm the safety and performance of Passeo-18 lx in infrainguinal arteries in a large population treated under real-world conditions with low complication rates and good clinical outcomes (NCT02276313).
Authors: Gunnar Tepe; Thomas Zeller; Thomas Albrecht; Stephan Heller; Uwe Schwarzwälder; Jean-Paul Beregi; Claus D Claussen; Anja Oldenburg; Bruno Scheller; Ulrich Speck Journal: N Engl J Med Date: 2008-02-14 Impact factor: 91.245
Authors: N Diehm; P M Pattynama; M R Jaff; A Cremonesi; G J Becker; L N Hopkins; F Mahler; A Talen; J F Cardella; S Ramee; M van Sambeek; F Vermassen; G Biamino Journal: Eur J Vasc Endovasc Surg Date: 2008-08-08 Impact factor: 7.069
Authors: Antonio Micari; Marianne Brodmann; Koen Keirse; Patrick Peeters; Gunnar Tepe; Martin Frost; Hong Wang; Thomas Zeller Journal: JACC Cardiovasc Interv Date: 2018-05-28 Impact factor: 11.195
Authors: Kenneth Rosenfield; Michael R Jaff; Christopher J White; Krishna Rocha-Singh; Carlos Mena-Hurtado; D Christopher Metzger; Marianne Brodmann; Ernst Pilger; Thomas Zeller; Prakash Krishnan; Roger Gammon; Stefan Müller-Hülsbeck; Mark R Nehler; James F Benenati; Dierk Scheinert Journal: N Engl J Med Date: 2015-06-24 Impact factor: 91.245
Authors: Krishna J Rocha-Singh; Sue Duval; Michael R Jaff; Peter A Schneider; Gary M Ansel; Sean P Lyden; Christopher M Mullin; John P A Ioannidis; Sanjay Misra; Abraham R Tzafriri; Elazer R Edelman; Juan F Granada; Christopher J White; Joshua A Beckman Journal: Circulation Date: 2020-05-06 Impact factor: 29.690
Authors: Gunnar Tepe; John Laird; Peter Schneider; Marianne Brodmann; Prakash Krishnan; Antonio Micari; Christopher Metzger; Dierk Scheinert; Thomas Zeller; David J Cohen; David B Snead; Beaux Alexander; Mario Landini; Michael R Jaff Journal: Circulation Date: 2014-12-03 Impact factor: 29.690
Authors: Herman Schroë; Andrew H Holden; Yann Goueffic; Shirley J Jansen; Patrick Peeters; Koen Keirse; Wulf Ito; Frank Vermassen; Antonio Micari; Erwin Blessing; Michael R Jaff; Thomas Zeller Journal: Catheter Cardiovasc Interv Date: 2017-10-31 Impact factor: 2.692
Authors: Prakash Krishnan; Peter Faries; Khusrow Niazi; Ash Jain; Ravish Sachar; William B Bachinsky; Joseph Cardenas; Martin Werner; Marianne Brodmann; J A Mustapha; Carlos Mena-Hurtado; Michael R Jaff; Andrew H Holden; Sean P Lyden Journal: Circulation Date: 2017-07-20 Impact factor: 29.690
Authors: Marianne Brodmann; Thomas Zeller; Johnny Christensen; Christoph Binkert; Lubomir Spak; Henrik Schröder; Paolo Righini; Giovanni Nano; Gunnar Tepe Journal: J Vasc Bras Date: 2017 Oct-Dec